Drug repurposing represents an excellent strategy for identifying new uses for approved or investigational drugs outside the original medical indication [17, 18], and, in this context, promising results have been achieved for the treatment of diseases caused by protozoa and trematodes with clinically approved HDAC inhibitors used against cancer [16, 19–22]. This evidence concerns the gene HDAC9 and cancer.